Investment Firm Nxt2b to Buy 49 Percent of Olink Bioscience
September 02, 2011
Investment Firm Nxt2b to Buy 49 Percent of Olink Bioscience
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Expanded Proximity Ligation Assay Could Prove Valuable for Biomarker Studies, Top-Down Proteomics
May 13, 2011 / ProteoMonitor - Some Proteomics Firms Exploring Next-Generation Sequencing for Biomarker Research
May 6, 2011 / ProteoMonitor - Genomics Key to Thermo's Life Tech Buy, but Implications for Proteomics, Multi-omics Work
April 19, 2013 / ProteoMonitor - Oligo-Based Protein Capture Tools Allow Simultaneous Reporting of Genetic, Proteomic Biomarker Data
October 21, 2011 / ProteoMonitor - Uppsala Team's ProteinSeq Assay Combines PLA and Next-Gen Sequencing for Protein Detection
October 7, 2011 / ProteoMonitor